November 13, 2025, Halifax, NS and Peachtree Corners, GA — Allumiqs and RayBiotech, a global innovator in protein array technology and biomarker discovery, are partnering to deliver a unified solution for translational science. This collaboration bridges advanced proteomics with multiomics analytics, enabling researchers to move seamlessly from discovery to clinic.
By combining RayBiotech’s proprietary antibody array and ELISA platforms with Allumiqs’ integrated multiomics workflows and advanced data analytics, the partnership creates a connected ecosystem supporting all stages of drug development — from discovery and preclinical through IND-enabling and CMC/clinical readiness. Customers gain access to GLP/CLIA bioanalytical, (companion) diagnostic development, and GMP protein production capabilities under one aligned framework.
“Together with RayBiotech, we’re empowering scientists with the ability to translate discovery into clinical impact more efficiently than ever before,” said Derek Gooderham, Chief Commercial Officer, Allumiqs. “Our combined expertise shortens timelines and amplifies the scientific return on every sample.”
“This collaboration embodies our shared commitment to accelerating translational success,” added Dr. Jarad Wilson, Director of Business Development, RayBiotech. “By integrating our technologies and services, we help researchers make confident, data-driven decisions that advance therapeutics faster.”
Key benefits of the partnership:
- Integrated proteomics-to-multiomics workflows across the full drug development continuum
- Accelerated biomarker validation and target discovery
- Unified data analysis to enhance decision-making and regulatory readiness
About RayBiotech Life, Inc.
RayBiotech is a leader in proteomics, providing cutting-edge tools and services that accelerate discovery in disease biology, biomarker validation, and therapeutic development. Its portfolio includes antibody arrays, ELISA kits, custom assay development, and central lab services for translational and clinical research. raybiotech.com
About Allumiqs
Allumiqs is a multiomics Contract Research Organization (CRO) specializing in proteomics, metabolomics, lipidomics, and small molecule analysis powered by advanced mass spectrometry. Delivering precise, high-impact data, Allumiqs helps biotech and biopharma organizations de-risk drug development and accelerate innovations from discovery to patient value. Collaborating with Allumiqs brings customers access to its dedicated team of scientists and world-class channel partners. allumiqs.com